Petition Call for reassessment of the Cancer Drugs Fund for blood cancer patients

More details

This is a petition on behalf of blood cancer patients who are concerned about the recent changes made to the Cancer Drugs Fund.
It was announced on Monday, January 12, 2015, that life-extending cancer drugs are to be removed from a list of medicines that are approved for funding via the Cancer Drugs Fund.

This petition calls specifically for a rethink over the de-listing of the following drugs:
Bosutinib and Dasatinib for blast-phase Chronic Myeloid Leukaemia;
The de-listing of Bortezomib for relapsed Myeloma, Mantle-Cell Lymphoma and Waldenstrom Macroglobulinemia;
The de-listing of Bendamustine for non-Hodgkin Lymphoma;
The de-listing of Ofatumumab for relapsed or refractory Chronic Lymphatic Leukaemia;
A re-analysis of the decision to reject Vemurafenib for all Hairy Cell Leukaemia patients and also a re-analysis of the rejection of Idelalisib for Chronic Lymphatic Leukaemia.

This petition closed early because of a General Election

730 signatures

10,000

Date closed 30 March 2015
Get petition data (json format)

About petition data

The data shows the number of people who have signed the petition by country as well as in the constituency of each Member of Parliament. This data is available for all petitions on the site. It is not a list of people who have signed the petition. The only name that is shared on the site is that of the petition creator.